These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23360784)

  • 1. The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.
    Tong X; Zhang X; Fan J; Tong Y; Li S; Jin J; Yao H
    Cancer Biol Ther; 2013 Apr; 14(4):370-7. PubMed ID: 23360784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
    Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
    Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
    Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
    J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.
    Yao HP; Luo YL; Feng L; Cheng LF; Lu Y; Li W; Wang MH
    Cancer Biol Ther; 2006 Sep; 5(9):1179-86. PubMed ID: 16880737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
    Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
    Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells.
    Li Z; Yao H; Guin S; Padhye SS; Zhou YQ; Wang MH
    Int J Oncol; 2010 Aug; 37(2):473-82. PubMed ID: 20596675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of RON mediated invasion of Raji cell line and drug-target effects].
    Zhan BC; Dong YH; Fan J; Yao HP; Jin J; Tong XM
    Zhonghua Xue Ye Xue Za Zhi; 2013 Nov; 34(11):926-30. PubMed ID: 24294846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
    O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
    Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
    Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
    Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
    Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
    Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase.
    Koh XY; Koh XH; Hwang LA; Ferrer FJ; Rahmat SAB; Lama D; Lane DP
    Oncogene; 2019 Nov; 38(48):7342-7356. PubMed ID: 31417186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD95-mediated apoptosis in Burkitt's lymphoma B-cells is associated with Pim-1 down-regulation.
    Matou-Nasri S; Rabhan Z; Al-Baijan H; Al-Eidi H; Yahya WB; Al Abdulrahman A; Almobadel N; Alsubeai M; Al Ghamdi S; Alaskar A; AlBalwi M; Alzahrani M; Alabdulkareem I
    Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):239-252. PubMed ID: 27641442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
    Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity.
    Guin S; Yao HP; Wang MH
    Mol Pharm; 2010 Apr; 7(2):386-97. PubMed ID: 20039696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells.
    Suthe SR; Yao HP; Weng TH; Wang MH
    Curr Cancer Drug Targets; 2023; 23(2):103-117. PubMed ID: 36028965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
    Chen E; Pei R
    J Int Med Res; 2020 May; 48(5):300060520926093. PubMed ID: 32468878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
    Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
    Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.
    Wang MH; Padhye SS; Guin S; Ma Q; Zhou YQ
    Acta Pharmacol Sin; 2010 Sep; 31(9):1181-8. PubMed ID: 20694025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway.
    Zhao H; Li S; Wang G; Zhao W; Zhang D; Wang F; Li W; Sun L
    Cancer Med; 2019 Aug; 8(9):4348-4358. PubMed ID: 31207099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.